Invention Grant
- Patent Title: Quinazoline based EGFR inhibitors
-
Application No.: US13155788Application Date: 2011-06-08
-
Publication No.: US08349856B2Publication Date: 2013-01-08
- Inventor: Changgeng Qian , Xiong Cai
- Applicant: Changgeng Qian , Xiong Cai
- Applicant Address: US MA Lexington
- Assignee: Curis, Inc.
- Current Assignee: Curis, Inc.
- Current Assignee Address: US MA Lexington
- Agency: Elmore Patent Law Group, P.C.
- Agent Edgar W. Harlan; Carolyn S. Elmore, Esq.
- Main IPC: A61K31/517
- IPC: A61K31/517
Abstract:
The present invention relates to quinazoline containing zinc-binding moiety based derivatives of formula I that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer.
Public/Granted literature
- US20110295004A1 QUINAZOLINE BASED EGFR INHIBITORS Public/Granted day:2011-12-01
Information query
IPC分类:
